(Q35184569)

7 August 2017

1 reference

title

Hepatotoxicity of hypolipidemic drugs (English)

1 reference

7 August 2017

1 reference

2

K Rajender Reddy

1 reference

7 August 2017

Javier L Parra

1

1 reference

7 August 2017

1 May 2003

1 reference

7 August 2017

Clinics in liver disease

1 reference

7 August 2017

7

1 reference

7 August 2017

2

1 reference

7 August 2017

415-433

1 reference

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

7 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900024-2

7 January 2021

Established risk factors and coronary artery disease: the Framingham Study.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900024-2

7 January 2021

The multiple risk factor intervention trial in the U.S. A summary of results at four years in special intervention and usual care men

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900024-2

7 January 2021

The West of Scotland Coronary Prevention Study: a trial of cholesterol reduction in Scottish men.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900024-2

7 January 2021

Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900024-2

7 January 2021

Animal safety and toxicology of simvastatin and related hydroxy-methylglutaryl-coenzyme A reductase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900024-2

7 January 2021

Mechanism of action and biological profile of HMG CoA reductase inhibitors. A new therapeutic alternative

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900024-2

7 January 2021

Lowering cholesterol concentrations and mortality: a quantitative review of primary prevention trials

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900024-2

7 January 2021

Should there be a moratorium on the use of cholesterol lowering drugs?

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900024-2

7 January 2021

Serum cholesterol and cancer risk: an epidemiologic perspective

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900024-2

7 January 2021

Cholesterol reduction and non-illness mortality: meta-analysis of randomised clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900024-2

7 January 2021

Hydrophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900024-2

7 January 2021

Long-term safety of hepatic hydroxymethyl glutaryl coenzyme A reductase inhibitors: the role of metabolism-monograph for physicians

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900024-2

7 January 2021

The interaction of diltiazem with lovastatin and pravastatin

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900024-2

7 January 2021

Effect of itraconazole on the pharmacokinetics of atorvastatin

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900024-2

7 January 2021

Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900024-2

7 January 2021

Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900024-2

7 January 2021

Defining patient risks from expanded preventive therapies

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900024-2

7 January 2021

Statin-fibrate combination therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900024-2

7 January 2021

HMG CoA reductase inhibitors. Current clinical experience

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900024-2

7 January 2021

Long-term safety and efficacy profile of simvastatin

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900024-2

7 January 2021

Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900024-2

7 January 2021

Myositis, microvesicular hepatitis, and progression to cirrhosis from troglitazone added to simvastatin

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900024-2

7 January 2021

[Toxic liver damage caused by HMG-CoA reductase inhibitor]

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900024-2

7 January 2021

Extended clinical safety profile of lovastatin

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900024-2

7 January 2021

Clinical experience with lovastatin.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900024-2

7 January 2021

The liver and lovastatin

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900024-2

7 January 2021

Lovastatin-induced acute cholestatic hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900024-2

7 January 2021

Acute hepatitis induced by HMG-CoA reductase inhibitor, lovastatin

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900024-2

7 January 2021

An overview of the clinical safety profile of atorvastatin (lipitor), a new HMG-CoA reductase inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900024-2

7 January 2021

Clinical implications of the biopharmaceutical properties of fluvastatin.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900024-2

7 January 2021

Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900024-2

7 January 2021

The Helsinki Heart Study: central findings and clinical implications

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900024-2

7 January 2021

The Helsinki Heart Study: an 8.5-year safety and mortality follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900024-2

7 January 2021

Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900024-2

7 January 2021

Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Lopid Coronary Angiography Trial (LOCAT) Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900024-2

7 January 2021

Comparative toxicity and safety profile of fenofibrate and other fibric acid derivatives

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900024-2

7 January 2021

Review of European clinical experience with fenofibrate

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900024-2

7 January 2021

Mechanism of action of fibrates on lipid and lipoprotein metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900024-2

7 January 2021

Micronized fenofibrate: a new fibric acid hypolipidemic agent

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900024-2

7 January 2021

Hepatic toxicity of unmodified and time-release preparations of niacin

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900024-2

7 January 2021

Niacin revisited: clinical observations on an important but underutilized drug.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900024-2

7 January 2021

Effects of niacin therapy that simulate neoplasia: hepatic steatosis with concurrent hepatic dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900024-2

7 January 2021

Transient focal hepatic defects related to sustained-release niacin.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900024-2

7 January 2021

Hepatotoxicity associated with sustained-release niacin

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900024-2

7 January 2021

Hepatitis and hematemesis complicating nicotinic acid use.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900024-2

7 January 2021

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900024-2

1 reference

7 January 2021

Niacin-induced hepatitis: a potential side effect with low-dose time-release niacin

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900024-2

7 January 2021

Rechallenge with crystalline niacin after drug-induced hepatitis from sustained-release niacin

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900024-2

7 January 2021

Niacin for lipid disorders.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900024-2

7 January 2021

Combination therapy with fluvastatin and niacin in hypercholesterolemia: a preliminary report on safety

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900024-2

7 January 2021

Intrahepatic cholestasis during nicotinic acid therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900024-2

7 January 2021

Delirium and lactic acidosis caused by ethanol and niacin coingestion

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900024-2

7 January 2021

Nicotinic acid-induced fulminant hepatic failure

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900024-2

7 January 2021

Colesevelam hydrochloride (cholestagel): a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900024-2

7 January 2021

The effects of cholestyramine on high density lipoprotein metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900024-2

7 January 2021

Colestipol-induced hepatotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900024-2

7 January 2021

Colesevelam hydrochloride: a non-absorbed, polymeric cholesterol-lowering agent

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900024-2

7 January 2021

The independent and combined effects of aerobic exercise and dietary fish intake on serum lipids and glycemic control in NIDDM. A randomized controlled study.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900024-2

7 January 2021

Differential effects of eicosapentaenoic acid and docosahexaenoic acid on vascular reactivity of the forearm microcirculation in hyperlipidemic, overweight men

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900024-2

7 January 2021

ApoE polymorphism and fish oil supplementation in subjects with an atherogenic lipoprotein phenotype.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900024-2

7 January 2021

Policosanol: clinical pharmacology and therapeutic significance of a new lipid-lowering agent

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900024-2

7 January 2021

Garlic powder and plasma lipids and lipoproteins: a multicenter, randomized, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900024-2

7 January 2021

10.1016/S1089-3261(03)00024-2

Identifiers

DOI

1 reference

7 August 2017

1 reference

PubMed ID

12879992